Pulmotect, Inc., a clinical-stage biotechnology company developing an inhaled pathogen-agnostic, host-directed immunomodulator (PUL-042), announces that Respiratory Medicine specialist Néstor A. Molfino, MD, has joined the company as President and Chief Executive Officer.
“Dr. Molfino brings to Pulmotect an impressive background of accomplishment in respiratory drug development,” said Leo E. Linbeck III, Chairman of the Board of Pulmotect. “We are pleased that the promise of Pulmotect’s novel approach to infection prevention and treatment were able to bring Néstor to Houston from San Francisco, and we look forward to continued progress at the company.”
Immediately prior to his position with Pulmotect, Dr. Molfino was an independent consultant to biopharmaceutical companies, clinical research organizations (CROs), investors and patient organizations in planning, designing and execution of drug development and commercial strategies. From 2012 to 2015, Dr. Molfino was the Chief Medical Officer at South San Francisco-based KaloBios Pharmaceuticals, Inc. Prior to that, he was Vice President, Clinical Development and Respiratory Therapeutic Area Head at MedImmune, Inc. (now part of AstraZeneca Biologics). Dr. Molfino started his career in the biopharmaceutical industry in 1994. Additionally, for the past 16 years Dr. Molfino has served as a pulmonary and allergy consultant to Fermin Salaberry, a non-profit public community hospital assisting underserved populations in Argentina.
Dr. Molfino received a Master’s Degree in Molecular and Cell Biology from the University of Toronto. He holds a Medical Degree from Universidad Nacional de Rosario in Argentina, completing an internship and residency in Internal Medicine and Respiratory Medicine, after which he completed a post-doctoral fellowship in lung physiology at the University of Toronto, where he was appointed assistant professor in 2004. In 2006, he was appointed Adjunct Professor at McGill University in Montreal, Canada.
“I am excited to join Pulmotect, a company that has a disruptive therapy to reduce the impact of respiratory infections in different patient populations. We will aim at reducing morbidity and ultimately mortality in patients suffering from immune suppression, chronic respiratory conditions and even in the general population in the case of pandemias from new emerging threats,” said Dr. Molfino. “Pulmotect has solid science, and I am thrilled to be part of an exceptional team as it works toward the goal of benefiting broad populations.”
Dr. Brenton Scott, a founder of Pulmotect and formerly President, has moved into the role of COO and Director of Business Development and Government Affairs. “Dr. Scott has been instrumental in bringing the company from the bench side to completing two Phase I studies in healthy volunteers. He will continue to be an integral part of our strategy and execution,” said Dr. Molfino.
Company Name: Pulmotect
Contact Person: Anna Halvorson
Country: United States